1. What does the typical assessment look like for someone’s first time pain-related visit? a. PROBE Can you guide me through what happened at a recent office visit for a
patient who came in for pain?
2. What are the main factors that influence your decision to prescribe opioid medications? 3. Upon prescribing an opioid pain medication for the first time to a patient, what kind of
discussion do you have with them?
a. PROBE Could you give me an example of a recent conversation that you had with a patient?
4. What do you think about the PDMP? Is it useful? When is it most useful? When is it least useful or you find that you don’t need to use it?
a. PROBE: Can you tell me about your encounters last week? Did you check the PDMP?
5. What are your thoughts on opioid or pain contracts? Do you find them useful or not useful?
a. PROBE: Can you tell me about the last time you used a pain contract? What was that conversation like?
6. What are your thoughts on urine drug testing? When do you use urine drug testing? a. PROBE: Can you tell me about the last time you used this test?
7. Have you used tools to assess patients for risk such as the Opioid Risk Tool? When was the last time you used the tool?
8. Do you discuss substance use with your patients?
a. How does that information affect your decision-making?
9. What do you think about the media coverage of opioids? Has this changed your practice in any way?
10. What are your thoughts of how health systems are handling opioid prescribing? 11. Have there been changes to how you think about prescribing opioid medications over
References
1. Substance Abuse and Mental Health Services Administration. SAMHSA opioid overdose prevention toolkit. SAMHSA Opioid Overdose Prevention Toolkit: HHS Publication Rockville, MD; 2013.
2. Centers for Disease Control and Prevention. CDC Guidelines for Prescribing Opioids for Chronic Pain: Guidelines at a Glance. In: Prevention CDC, editor. 2016.
3. Jones CM. Heroin use and heroin use risk behaviors among nonmedical users of
prescription opioid pain relievers – United States, 2002–2004 and 2008–2010. Drug and Alcohol Dependence. 2013;132(1):95-100.
4. Rudd R, Aleshire N, Zibbell J, Gladden R. Increases in drug and opioid overdose deaths— United States 2000–2014. Morbidity and Mortality Weekly Report. 2016;64:1374-82.
5. Seth P, Rudd RA, Noonan RK, Haegerich TM. Quantifying the Epidemic of Prescription Opioid Overdose Deaths. American Journal of Public Health. 2018;108(4):500-2.
6. Chou R. 2009 clinical guidelines from the American Pain Society and the American Academy of Pain Medicine on the use of chronic opioid therapy in chronic noncancer pain: what are the key messages for clinical practice? Pol Arch Med Wewn. 2009;119.
7. Ali MM, Dowd WN, Classen T, Mutter R, Novak SP. Prescription drug monitoring
programs, nonmedical use of prescription drugs, and heroin use: Evidence from the National Survey of Drug Use and Health. Addictive Behaviors. 2017;69:65-77.
8. Argoff CE, Alford DP, Fudin J, Adler JA, Bair MJ, Dart RC, et al. Rational Urine Drug Monitoring in Patients Receiving Opioids for Chronic Pain: Consensus Recommendations. Pain Medicine. 2018;19(1):97-117.
9. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the opioid risk tool. Pain medicine (Malden, Mass). 2005;6.
10. Starrels JL, Becker WC, Alford DP, Kapoor A, Williams AR, Turner BJ. Systematic Review: Treatment Agreements and Urine Drug Testing to Reduce Opioid Misuse in Patients With Chronic Pain. Annals of Internal Medicine. 2010;152(11):712-20.
11. National Conference of State Legislatures. Prescribing policies: States confront opioid overdose epidemic Washington, D.C.2018 [updated April 4, 2018.
12. Winstanley EL, Zhang Y, Mashni R, Schnee S, Penm J, Boone J, et al. Mandatory review of a prescription drug monitoring program and impact on opioid and benzodiazepine dispensing. Drug and Alcohol Dependence. 2018;188:169-74.
13. McBane S, Weigle N. Is it time to drug test your chronic pain patient? The Journal of family practice. 2010;59(11):628-33.
14. Centers for Disease Control and Prevention. Quality Improvement and Care Coordination: Implementing the CDC Guideline for Prescribing Opioids for Chronic Pain. Atlanta, GA: National Center for Injury Prevention and Control, Division of Unintentional Injury Prevention; 2018. 15. Kilaru AS, Gadsden SM, Perrone J, Paciotti B, Barg FK, Meisel ZF. How Do Physicians Adopt and Apply Opioid Prescription Guidelines in the Emergency Department? A Qualitative Study. Annals of Emergency Medicine. 2014;64(5):482-9.e1.
16. Hariharan J, Lamb GC, Neuner JM. Long-Term Opioid Contract Use for Chronic Pain Management in Primary Care Practice. A Five Year Experience. Journal of General Internal Medicine. 2007;22(4):485-90.
17. Hildebran C, Cohen D, Irvine J, Foley C, O'Kane N, Beran T, et al. How clinicians use prescription drug monitoring programs: a qualitative inquiry. Pain medicine (Malden, Mass). 2104;15(7):1526-4637.
18. Leichtling GJ, Irvine JM, Hildebran C, Cohen DJ, Hallvik SE, Deyo RA. Clinicians' Use of Prescription Drug Monitoring Programs in Clinical Practice and Decision-Making. Pain medicine (Malden, Mass). 2017;18(6):1063-9.
19. Starrels JL, Wu B, Peyser D, Fox AD, Batchelder A, Barg FK, et al. It made my life a little easier: primary care providers' beliefs and attitudes about using opioid treatment agreements. J Opioid Manag. 2014;10(2):95-102.
20. Charmaz K. Constructing grounded theory: A practical guide through qualitative analysis. Second edition. Thousand Oaks, CA: Sage; 2014 2014.
21. Blumer H. What is Wrong with Social Theory? American Sociological Review. 1954;19(1):3- 10.
22. Saldana J. The Coding Manual for Qualitative Researchers. London, UK: Sage Publications, Inc.; 2009.
23. Corbin J, Strauss AC. Basics of Qualitative Research: Techniques and Procedures for Developing Grounded Theory. Thousand Oaks, CA: Sage Publications, Inc.; 2008 2008//.
24. Buchman DZ, Ho A. What's trust got to do with it? Revisiting opioid contracts. Journal of Medical Ethics. 2013.
25. Kaye AD, Marshall ZJ, Lambert SM, Trescot AM, Prabhakar A, Elhassan AO, et al. Ethical perspectives on urine drug screening for pain physicians. Pain Physician. 2014;17(5):E559-64. 26. Chapman L, dela Cruz AM, Hutto J. Opioid Treatment Agreements: Helpful or Hurtful? American Journal of Psychiatry Residents' Journal. 2016;11(9):14-6.
27. Collen M. Opioid Contracts and Random Drug Testing for People with Chronic Pain — Think Twice. The Journal of Law, Medicine & Ethics. 2009;37(4):841-5.
28. Ghods MP, Schmid IT, Pamer CA, Lappin BM, Slavin DC. Developing and Initiating Validation of a Model Opioid Patient-Prescriber Agreement as a Tool for Patient-Centered Pain Treatment.
29. Wallace LS, Keenum AJ, Roskos SE, McDaniel KS. Development and Validation of a Low- Literacy Opioid Contract. The Journal of Pain. 2007;8(10):759-66.
30. Tobin DG, Keough Forte K, Johnson McGee S. Breaking the pain contract: A better controlled-substance agreement for patients on chronic opioid therapy. Cleveland Clinic journal of medicine. 2016;83(11):827-35.
31. Klein KJ, Sorra JS. The Challenge of Innovation Implementation. The Academy of Management Review. 1996;21.
32. Payne R, Twillman R. Policy Brief: Opioid Treatments or “Contracf”: Proceed with Caution. Kansas, MO: Center for Practical Bioethics; 2014 2014.
33. Chaudhary S, Compton P. Use of risk mitigation practices by family nurse practitioners prescribing opioids for the management of chronic nonmalignant pain. Substance abuse. 2017;38(1):95-104.
34. Starrels JL, Becker WC, Weiner MG, Li X, Heo M, Turner BJ. Low Use of Opioid Risk Reduction Strategies in Primary Care Even for High Risk Patients with Chronic Pain. Journal of General Internal Medicine. 2011;26(9):958-64.
35. Albrecht JS, Khokhar B, Pradel F, Campbell M, Palmer J, Harris I, et al. Perceptions of patient provider agreements. Journal of Pharmaceutical Health Services Research. 2015;6(3):139-44. 36. Fishman SM, Bandman TB, Edwards A, Borsook D. The Opioid Contract in the
Management of Chronic Pain. Journal of Pain and Symptom Management. 1999;18(1):27-37. 37. Finley EP, Garcia A, Rosen K, McGeary D, Pugh MJ, Potter JS. Evaluating the impact of prescription drug monitoring program implementation: a scoping review. BMC Health Serv Res. 2017;17(1):420.
38. National Alliance for Model State Drug Laws. Mandated Use of State Prescription Drug Monitoring Programs. National Alliance for Model State Drug Laws; 2016 November 8, 2016. 39. Chou R, Deyo R, Devine B, Hansen R, Sullivan S, Jarvik JG, et al. The Effectiveness and Risks of Long-Term Opioid Treatment of Chronic Pain. Rockville, MD: Agency for Healthcare Research and Quality; 2014.
CHAPTER 3: Study 2 : Understanding Clinicians’ Decisions to Assume Prescriptions for